Founded in 2004, ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen is a natural blood protein that plays a pivotal role in blood clotting and tissue healing.
FibrocapsTM, the company’s lead biologic, is a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical fibrin sealant being developed to stop bleeding during or after surgery. Fibrocaps is clearly differentiated from existing liquid tissue sealants and hemostats: it is ready for immediate use, and is stable at room temperature.
ProFibrix is also committed to establishing a versatile and commercially feasible recombinant production platform for human fibrinogen to enable the development of new, advanced products. The ProFibrix platform is also designed to allow production to be easily scalable to meet any demand.
ProFibrix is headquartered in Leiden, the Netherlands, with a subsidiary in Seattle, WA. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field.
